1
|
NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma. J Transl Med 2018; 98:219-227. [PMID: 28991262 DOI: 10.1038/labinvest.2017.105] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/22/2017] [Accepted: 07/24/2017] [Indexed: 12/20/2022] Open
Abstract
NDPK-A, encoded by nm23-H1 (also known as NME1) was the first metastasis suppressor discovered. Much of the attention has been focused on the metastasis-suppressing role of NDPK-A in human tumors, including breast carcinoma and melanoma. However, compelling evidence points to a metastasis-promoting role of NDPK-A in certain tumors such as neuroblastoma and lymphoma. To balance attention on this contrariety of NDPK-A in different cancer types, this review addresses the metastasis-promoting role of NDPK-A in neuroblastoma. Neuroblastoma is an embryonic tumor, arising from neural crest cells that fail to differentiate into the sympathetic nervous system. We summarize and discuss nm23-H1 genetics and the prognosis of neuroblastoma, structural and functional changes associated with the S120G mutation of NDPK-A, as well as the evidence supporting the role of NDPK-A as a metastasis promoter. Also discussed are the NDPK-A relevant molecular determinants of neuroblastoma metastasis, and metastasis-relevant neural crest development. Because of NDPK-A's dichotomous role in tumor metastasis as both a suppressor and a promoter, tumor genome/exome profiles are necessary to identify the molecular drivers of metastasis in the NDPK-A network for developing tumor-specific therapies.
Collapse
|
2
|
Perisa MM, Sarcevic B, Troselj KG, Grsic K, Sitic S, Seiwerth S. Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma. Oncol Lett 2017; 13:3547-3555. [PMID: 28521457 PMCID: PMC5431143 DOI: 10.3892/ol.2017.5876] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Accepted: 01/06/2017] [Indexed: 12/19/2022] Open
Abstract
The expression of non-metastatic expressed/non-metastatic 23 nucleoside diphosphate kinase 1 (nm23-H1) and cyclooxygenase 2 (COX-2) proteins in thyroid carcinoma have been analysed in a number of previous studies, but this requires further study. The current study focused on the expression levels of nm23-H1 and COX-2 in 130 human thyroid papillary carcinoma (PTC) tissues. Of the 130 PTC tissues, 55 were classified as microcarcinoma and may provide information on the development of the specific characteristics of this tumour type. Routine histopathological examination and immunohistochemical detection of nm23-H1 and COX-2 expression was performed on 130 PTC tissues from patients treated in the Clinical Hospital for Tumours (Zagreb, Croatia) between January 2000 and December 2007. The stain intensity of nm23-H1 and COX-2 proteins was compared with the characteristics of the patients and the tumour. The highest overall expression rate of nm23-H1 and COX-2 was 90 and 67.6%, respectively, and the joint expression of these proteins was statistically significant. The median expression level of nm23-H1 was significantly increased in the classical and follicular histological group of the PTC tissues compared with tissues from other histological groups. The median expression level of COX-2 was significantly increased in the follicular histological group, and reduced in the diffuse-sclerosing group of PTC tissues. All the metastatic microcarcinoma tissues had increased expression levels of the two proteins in comparison with microcarcinoma tissues without lymph node metastases; however, this variation was only statistically significant for COX-2 expression levels. Therefore the results of the current study indicate that COX-2 protein levels may be able to differentiate which thyroid papillary microcarcinoma tumours possess metastatic potential.
Collapse
Affiliation(s)
- Marija Milkovic Perisa
- Department of Pathology, School of Medicine, University Hospital for Tumours, Sisters of Charity Clinical Hospital Center, Zagreb 10000, Croatia.,Department of Pathology, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| | - Bozena Sarcevic
- Department of Pathology, School of Medicine, University Hospital for Tumours, Sisters of Charity Clinical Hospital Center, Zagreb 10000, Croatia
| | - Koraljka Gall Troselj
- Laboratory for Epigenomics, Division of Molecular Medicine, Rudjer Bošković Institute, Zagreb 10000, Croatia
| | - Kresimir Grsic
- Division of Head and Neck Surgery, Department of Surgical Oncology, University Hospital for Tumours, Sisters of Charity Clinical Hospital Center, Zagreb 10000, Croatia
| | - Sanda Sitic
- Department of Pathology, School of Medicine, University Hospital for Tumours, Sisters of Charity Clinical Hospital Center, Zagreb 10000, Croatia
| | - Sven Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
| |
Collapse
|
3
|
Fan Y, Yao Y, Li L, Wu Z, Xu F, Hou M, Wu H, Shen Y, Wan H, Zhou Q. nm23-H1 gene driven by hTERT promoter induces inhibition of invasive phenotype and metastasis of lung cancer xenograft in mice. Thorac Cancer 2013; 4:41-52. [PMID: 28920323 DOI: 10.1111/j.1759-7714.2012.00140.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Lung cancer is the leading cause of cancer death in both men and women worldwide. Tumor metastasis is an essential aspect of lung cancer progression and patient death. The nm23-H1 gene has been extensively investigated as a metastasis suppressor gene. Our previous studies have revealed: that a significant relationship exists between the low-level expression nm23-H1 in primary non-small cell lung cancer (NSCLC) with increased metastasis and a poor prognosis; that L9981-nm23-H1 cells (a nm23-H1 transfactant cell) exhibited lower cell proliferation rates, more G0/G1 phase growth, and an increase in apoptosis with a dramatic decrease in the tumor cells' ability to invade than L9981 cells did; and that L9981- nm23-H1 cells also demonstrated a significantly reduced lymph node and distant metastatic capacity in vivo than L9981 cells did in nude mice. METHODS In this study, we construct a plasmid containing the nm23-H1 gene, which was driven by the human telomerase reverse transcriptase (hTERT) promoter. We evaluated the anti-invasion and anti-metastatic effects of pGL3-hTP-nm23 on L9981, a human large cell lung cancer cell line with nm23-H1 negative expression, by transwell assay in vitro and bioluminescence in nude mice models. The toxicity of pGL3-hTP-nm23 and its effects on tumor growth were evaluated in nude mice models after gene therapy. The cell cycles, apoptosis, and proliferation of the nm23-H1 transfactant were also detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay) and flow cytometry (FCM). RESULTS The results showed that the hTERT-promoter dramatically drives nm23-H1 gene expression, and induces inhibition of cell growth and migration in L9981-luc cells and MRC-5 cells in vitro. nm23-H1 also significantly inhibited the tumorigenesis and distant metastasis of L9981-luc cell in vivo. Moreover, no obvious side effect was detected in normal mouse tissues after intratumoral injection of the vector. CONCLUSION The treatment of the nm23-H1 gene driven by hTERT promoter appears to be a promising approach for the gene therapy of nm23-H1 low-expressed tumors.
Collapse
Affiliation(s)
- Yu Fan
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yibing Yao
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Lu Li
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Zhihao Wu
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Feng Xu
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Mei Hou
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Heng Wu
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yali Shen
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Haisu Wan
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Qinghua Zhou
- The Key Laboratory of Lung Cancer Molecular Biology in Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| |
Collapse
|
4
|
Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract 2009; 205:83-7. [DOI: 10.1016/j.prp.2008.08.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2008] [Revised: 08/05/2008] [Accepted: 08/22/2008] [Indexed: 11/23/2022]
|
5
|
Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW. Discovery and Validation of Protein Abundance Differences between Follicular Thyroid Neoplasms. Cancer Res 2008; 68:1572-80. [DOI: 10.1158/0008-5472.can-07-5020] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Hedley BD, Allan AL, Chambers AF. Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncol 2007; 2:627-41. [PMID: 17026454 DOI: 10.2217/14796694.2.5.627] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Metastasis, or tumor growth in an ectopic site, may occur several years after apparently successful treatment of the primary malignancy. Clinical dormancy is seen in a large number of cancer patients, but once growth in an ectopic site initiates, current adjuvant therapies are inadequate and the majority of patients with metastatic disease will die. Many genes may regulate ectopic growth in a secondary site, including a small subset, termed the metastasis suppressor genes. Investigation into this class of genes holds promise in terms of gaining a greater understanding of tumor dormancy and how the process of metastasis may be naturally inhibited. This review will focus on the role of metastasis suppressor genes in tumor dormancy. Insights into the metastatic process from studies of metastasis suppressor genes may lead to novel targets for antimetastatic therapy through drug-induced reactivation of one or more of these genes and/or their respective signaling pathways.
Collapse
Affiliation(s)
- Benjamin D Hedley
- University of Western Ontario, Schulich School of Medicine & Dentistry, London Regional Cancer Program, Department of Oncology, London, Ontario, Canada.
| | | | | |
Collapse
|
7
|
Yalçinkaya U, Özuysal S, Bilgin T, Ercan I, Saraydaroglu Ö, Demir D. Nm23 expression in node-positive and node-negative endometrial cancer. Int J Gynaecol Obstet 2006; 95:35-9. [DOI: 10.1016/j.ijgo.2006.03.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2005] [Revised: 03/16/2006] [Accepted: 03/21/2006] [Indexed: 01/28/2023]
|
8
|
Ling KS, Chen GD, Tsai HJ, Lee MS, Wang PH, Liu FS. Genetic Changes in Ovarian Cancer. Taiwan J Obstet Gynecol 2005. [DOI: 10.1016/s1028-4559(09)60144-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
|
9
|
|
10
|
Tas F, Tuzlali S, Aydiner A, Saip P, Salihoglu Y, Iplikci A, Topuz E. Prognostic role of nm23 gene expression in patients with ovarian cancer. Am J Clin Oncol 2002; 25:164-7. [PMID: 11943895 DOI: 10.1097/00000421-200204000-00012] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The aim of the study was to define the prognostic role of the metastasis suppressor gene, nm23, in 50 patients with primary ovarian cancer. Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded specimens by the primary nm23 monoclonal antibody (Novocastra, NCL-nm23 clone 37.6). Forty-two specimens (84%) showed a positive nm23 staining. The nm23 staining was more intensive in patients with normal serum CA19.9 levels, patients with nonrecurrent disease, and alive patients (p < 0.05). Nm23 expression did not correlate with common clinicopathologic parameters such as histology, grade of differentiation, International Federation of Gynecology and Obstetrics stage, and CA-125. Although the difference was not statistically significant (p = 0.11), we found that nm23 may have a favorable prognostic factor in ovarian cancer. To clarify this subject further, prospective studies on a larger population are needed.
Collapse
Affiliation(s)
- Faruk Tas
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | | | | | | | | | | | | |
Collapse
|
11
|
Indinnimeo M, Cicchini C, Stazi A, Giarnieri E, Limiti MR, Ghini C, Vecchione A. nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? J Surg Oncol 2000; 74:163-6. [PMID: 10914829 DOI: 10.1002/1096-9098(200006)74:2<163::aid-jso16>3.0.co;2-d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND OBJECTIVES Anatomic extent is not the sole axis of classification of tumors and of tumor patients relevant to treatment planning and estimation of prognosis. This results in the need to demonstrate an improvement in prognostic assessment and choice of therapy achieved by consideration of factors other than TNM. nm23 protein does prevent tumor from metastasizing and may also play a role in the control of growth and development. The purpose of this study was to elucidate the clinical significance of nm23 expression in human anal canal carcinoma and to evaluate its influence on the outcome of patients after surgery or radiochemotherapy. METHODS Twenty-two patients affected by anal canal carcinoma were evaluated. Each section was incubated with monoclonal antibody nm23 NDPK-A. Immunostaining was considered positive when at least 10% of the tumor cells were immunostained. RESULTS nm23 immunoreactivity was detected in 6/22 (27.3%) tumors. No significant association was found between nm23 expression and prognosis. CONCLUSIONS The mechanisms causing enhanced nm23-H1 expression in anal canal carcinoma are unknown. Although the level and expression were not correlated with prognosis, activation of nm23-H1 gene might be a prerequisite for oncogenesis in this type of tumor, while an alternate possibility is the modification of cellular characteristics in relation to proliferation and/or differentiation as a consequence of oncogenesis.
Collapse
Affiliation(s)
- M Indinnimeo
- 1st Department of Surgery, University of Rome La Sapienza, Italy
| | | | | | | | | | | | | |
Collapse
|
12
|
Volm M, Mattern J, Koomägi R. Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas. Clin Exp Metastasis 1998; 16:595-602. [PMID: 9932606 DOI: 10.1023/a:1006588601683] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Twelve non-small cell lung carcinomas and adjacent normal lung tissues were examined for mutations of the nm23-H1 gene by using SSCP analysis and for an expression of the nm23-H1 protein by immunohistochemistry. No mutations could be found in either the carcinomas or in the adjacent normal tissues. In contrast, six of 12 carcinomas showed protein expression while only one adjacent normal lung tissue yielded a positive staining result. Therefore, the expression of nm23-H1 protein was analysed in a larger group of non-small cell lung carcinomas (n = 185) to determine whether or not the expression of nm23 protein may be of prognostic relevance. Only a weak relationship between nm23-H1 expression and lymph node involvement was observed. However, a significant correlation between proliferation and nm23-H1 expression was detected. Additionally, a direct correlation between apoptosis and nm23-H1 expression or between myc and nm23-H1 expression was found. Finally, non-small cell lung carcinomas that expressed nm23-H1 protein were more frequently sensitive to doxorubicin than carcinomas that did not express this protein.
Collapse
Affiliation(s)
- M Volm
- Department of Oncological Diagnostics and Therapy, German Cancer Research Center, Heidelberg
| | | | | |
Collapse
|
13
|
Martin K, King A, O'Neill K, Kandanearatchi A, Liyanage K, Pilkington GJ. Expression of the candidate invasion suppressor gene, nm23, in human brain tumors. Neuropathology 1998. [DOI: 10.1111/j.1440-1789.1998.tb00121.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
14
|
|
15
|
Royds JA, Robinson MH, Stephenson TJ, Rees RC, Fisher C. The association between nm23 gene expression and survival in patients with sarcomas. Br J Cancer 1997; 75:1195-200. [PMID: 9099969 PMCID: PMC2222803 DOI: 10.1038/bjc.1997.204] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The relationship between the expression of nm23, a putative metastasis-suppressor gene and prognosis was determined for 88 patients with sarcomas. Immunohistochemistry using immunopurified anti-nm23 peptide antibodies was performed and the results of each case graded according to the degree of staining. Univariate and multivariate analyses were carried out to determine the prognostic significance of nm23 staining for sarcoma patients. Expression of nm23 was found to increase in line with metastatic potential in many cases but this did not reach significance for the study as a whole. However, the possibility of nm23 loss occurring in association with metastasis cannot be ruled out in some more aggressive sarcomas, as was demonstrated for six patients with low-scoring, unclassified and synovial sarcomas that had metastasized. The time to metastasis was longer for patients with grade 3 sarcomas (50-75% of tumour cells staining) than similar patients in other staining groups. These results suggest that expression of nm23 genes in sarcomas is variable and has no value as a prognostic indicator for these mesenchymal tumours.
Collapse
Affiliation(s)
- J A Royds
- Department of Pathology, University of Sheffield Medical School, UK
| | | | | | | | | |
Collapse
|
16
|
Oda Y, Walter H, Radig K, Röse I, Neumann W, Roessner A. Immunohistochemical analysis of nm23 protein expression in malignant bone tumors. J Cancer Res Clin Oncol 1995; 121:667-73. [PMID: 7593131 DOI: 10.1007/bf01218525] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Expression levels of nm23 protein in 72 malignant bone tumors comprising 41 osteosarcomas, 22 chondrosarcomas, 6 Ewing's sarcomas, and 2 malignant fibrous histiocytomas were examined immunohistochemically, using anti-nm23 protein polyclonal antibody, and compared with 51 cases of benign bone tumors or tumor-like lesions. Malignant bone tumors showed significantly higher nm23 protein expression than benign bone tumors or tumor-like lesions (P < 0.0001). In chondrosarcoma, nm23 expression increased in high-grade tumors (grade I versus grade II and III: P = 0.0229). In the cases of osteosarcoma, however, grade IV osteosarcomas showed decreased expression of nm23 compared with grade III tumors (P = 0.0122). There was no significant relationship between nm23 expression and histological type. nm23 expression had no correlation with metastatic potential in osteosarcoma, although the therapy was not uniform in our cases. Furthermore, in 6 cases of osteosarcoma and 1 case of Ewing's sarcoma, there was no clear tendency for a decrease of nm23 in the metastatic sites compared with primary sites, as reported in breast cancer. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma.
Collapse
Affiliation(s)
- Y Oda
- Institute of Pathology, Faculty of Medicine, Ottovon-Guericke University Magdeburg, Germany
| | | | | | | | | | | |
Collapse
|
17
|
Holm R, Høie J, Kaalhus O, Nesland JM. Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinomas of the thyroid gland. Virchows Arch 1995; 427:289-94. [PMID: 7496599 DOI: 10.1007/bf00203397] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Reduced expression of nm23/NDP kinase and increased expression of cathepsin D seem to be correlated with the high metastatic potential in a variety of malignancies. The expression of nm23/NDP kinase and that of cathepsin D have been evaluated by means of an immunohistochemical technique in paraffin-embedded tissues from 44 primary medullary carcinomas of the thyroid gland (MCT) and from the corresponding lymph node metastases in 32 of these cases. In addition, lymph node metastases from 4 cases were studied. We found that 36 of 44 (82%) primary and 26 of 36 (72%) lymph node metastatic MCT were nm23/NDP kinase positive, whereas 14 of the 44 (32%) primary and 17 of the 36 (47%) lymph node metastatic MCT were cathepsin D positive. We found no indication that the nm23/NDP kinase level has any prognostic significance in MCT. The cathepsin D level is close to being prognostically significant in this study, and we cannot exclude the possibility that it could be of prognostic value. However, it seems to be quite weak, and therefore of little use in a clinical situation.
Collapse
Affiliation(s)
- R Holm
- Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
18
|
Walther MM, Anglard P, Gnarra J, Pozzatti R, Venzon D, De La Rosa A, Macdonald NJ, Steeg PS, Linehan WM. Expression of NM23 in Cell Lines Derived from Patients with Metastatic Renal Cell Carcinoma. J Urol 1995. [DOI: 10.1016/s0022-5347(01)67294-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- McClellan M. Walther
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Patrick Anglard
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - James Gnarra
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Rudy Pozzatti
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - David Venzon
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Abel De La Rosa
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Nicholas J. Macdonald
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Patricia S. Steeg
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - W. Marston Linehan
- Urologic Oncology Section, Surgery Branch and the Women's Cancer Section, Laboratory of Pathology, Biostatistics and Data Management Sections, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|